Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX)

Q: What does CUSIP 501976104 represent in this 13F holders report?

CUSIP 501976104 is the security identifier for KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share used to aggregate holder disclosures.

Q: How many institutions held KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share in Q4 2025?

99 institutional investors reported KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 501976104

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class: Equity / Common Stock, par value $0.00001 per share
Total 13F shares: 34,131,760
Total 13F value: $320,775,226
Share change: +11,302,004
Put/Call ratio: 116%
SEC-reported price per share: $9.40
Number of holders: 99
Value change: +$111,162,333
Number of buys: 61
Number of sells: 30
Shares outstanding: 56,833,213

Security key

501976104

Report period

Q4 2025

Institutions

Top holders

KYTX full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 Kyverna Therapeutics, Inc. SEC filings Kyverna Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 501976104

Newer quarter: Q1 2026 Previous quarter: Q3 2025

Recent filing periods:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Ownership snapshot

Top reported holders of KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Westlake BioPartners Fund...

Disclosed value leader

Westlake BioPartners Fund...

Comparable rows

15/15

Latest evidence

31 Dec 2025

13D/G 3/4/5 13F Lead comparable stake: 7.8% 13D/G row: Westlake BioPartners Fund I, L.P. Showing 1-6 of 15 holder rows.

Quick read

Westlake BioPartners Fund I, L.P. leads the comparable SEC ownership view at 7.8%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Westlake BioPartners Fund I, L.P.'s linked filing trail.

Comparable ownership Top 5

Westlake BioPartners Fund I, L.P. 7.8%

GordonMD Global Investments LP 7%

Northpond Ventures III, LP 6.1%

Bain Capital Life Sciences Opport... 5.4%

Westlake BioPartners Opportunity ... 1.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Westlake BioPartners Fund I, L.P.	13D/G 3/4/5 Dr. Beth C. Seidenberg ("Seidenberg") · 10%+ Owner 13D/G 3/4/5	7.8%	$43,778,216 4,657,257 shares	$0	31 Dec 2025
GordonMD Global Investments LP	13D/G 13D/G	7%	$23,275,071 3,058,485 shares	$0	13 Nov 2025
Northpond Ventures III, LP	13D/G Michael P. Rubin 13D/G	6.1%	$28,531,978 3,466,826 shares	$0	31 Dec 2025
Bain Capital Life Sciences Opportunities III, LP	13D/G 13D/G	5.4%	$25,595,300 3,110,000 shares	$0	31 Dec 2025
Westlake BioPartners Opportunity Fund I, L.P.	3/4/5 10%+ Owner 3/4/5	1.5%	$6,519,877 869,317 shares	+$999,998	18 Dec 2025
Vida Ventures Advisors, LLC	13F Company 13F	8%	$27,143,544 4,523,924 shares	—	30 Sep 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

34,131,760

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 value	Q4 2025 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend